MorphoSys AG (MorphoSys)

Oncology Corporate Profile

HQ Location

Lena-Christ-Strasse 48
82152 Martinsried, Planegg, G

Company Description

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
MOR208 (XmAbŒ5574)anti-CD19 monoclonal antibody (humanized)Acute Lymphocytic Leukemia (ALL)II
MOR208 (XmAbŒ5574)anti-CD19 monoclonal antibody (humanized)Chronic Lymphocytic Leukemia (CLL)IIXencor, Inc.
MOR202anti-CD38 monoclonal antibodyMultiple MyelomaIICelgene
BHQ880anti-DKK-1 monoclonal antibodyMultiple MyelomaIINovartis
MOR208 (XmAbŒ5574)anti-CD19 monoclonal antibody (humanized)Non-Hodgkin's Lymphoma (NHL)II
MOR209/ES414anti-PSMA/anti-CD3 bi-specific antibodyProstate cancerIIEmergent
CNTO 888anti-CCL2 monoclonal antibodyVarious cancer typesIIJanssen
vantictumab / OMP-18R5Wnt signaling pathway inhibitorBreast cancerIOncoMed
bimagrumabmonoclonal antibodyCancer cachexiaINovartis
BAY 94-9343anti-mesothelin antibody-drug conjugateMesotheliomaIBayer / Immunogen
vantictumab / OMP-18R5Wnt signaling pathway inhibitorNon Small Cell Lung Cancer (NSCLC)IOncoMed
BAY 94-9343anti-mesothelin antibody-drug conjugateOvarian cancerIBayer / Immunogen
BAY 94-9343anti-mesothelin antibody-drug conjugatePancreatic cancerIBayer / Immunogen
OMP-59R5monoclonal antibody anti-notch receptorPancreatic cancerIOncoMed
vantictumab / OMP-18R5Wnt signaling pathway inhibitorPancreatic cancerIOncoMed
MOR208 (XmAbŒ5574)anti-CD19 monoclonal antibody (humanized)Small Cell Lung Cancer (SCLC)I
OMP-59R5monoclonal antibody anti-notch receptorSmall Cell Lung Cancer (SCLC)IOncoMed
BAY 94-9343anti-mesothelin antibody-drug conjugateVarious cancer typesIBayer / Immunogen
OMP-59R5monoclonal antibody anti-notch receptorVarious cancer typesIOncoMed
vantictumab / OMP-18R5Wnt signaling pathway inhibitorVarious cancer typesIOncoMed
BI 836845IGF ligand neutralizing antibodyVarious cancer typesIBoehringer Ingelheim
LJM716anti-HER3 antibodyVarious cancer typesINovartis
PF-050825664-1BB agonist monoclonal antibodyVarious cancer typesIPfizer

View additional information on product candidates here »


Recent News Headlines

There are no news items to display